Source: Opexa Therapeutics, Inc.
On Friday August 7, 2009,
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc., a company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today announced that it has entered into an exclusive agreement with Novartis, one of the world’s largest pharmaceutical companies, for the further development of Opexa’s novel stem cell technology. This technology, which has generated preliminary data showing the potential to generate monocyte derived islet cells from peripheral blood mononuclear cells, was in early preclinical development at Opexa.
Under the terms of the agreement, Novartis will acquire the stem cell technology from Opexa and Novartis will have full responsibility for funding and carrying out all research, development and commercialization activities.
To continue, click here
..............................................................................................
Learn more of Multiple Sclerosis when registered at: http://www.msviewsandnews.org.
Once registered, you will receive our weekly ms related e-newsletter, keeping you informed of current MS information.This e-Newsletter is now being received by e-recipients in (53) Countries.
Visit and Use our MS Blog - and Our Library of MS Archives, to your advantage.
Become A Fan of "MS Views and News" on Facebook
and Here is a link to Join our "MS Views and News" cause
Please don't forget to tell others that are affected by MS, of our website, blog and e-newsletter. If not yet registered, visit: http://www.msviewsandnews.org
-- Have questions? Write to: stuart@msviewsandnews.org Thank You
============================================
0 comments:
Post a Comment